New Gene Therapy Platform Uses the Brain's Glymphatic System to Bypass the Blood-Brain Barrier

A team of researchers at the University of Rochester Medical Center has developed a gene therapy platform that uses the brain's natural glymphatic system to bypass the blood-brain barrier (BBB) and deliver therapeutic genes broadly throughout the brain. Published in Nature Biotechnology in July 2025, the platform combines two innovations — in vivo selection of capsid variants in human glial chimeric mice and glymphatic delivery via cisterna magna injection — to target glial cells while minimizing exposure to peripheral organs like the liver .

How the Platform Works

The platform leverages the glymphatic system, a fluid-clearance network first discovered at the University of Rochester by co-author Maiken Nedergaard. Instead of forcing viral vectors through the BBB from the bloodstream — a notoriously difficult route — the researchers deliver engineered AAV5 capsids into the cisterna magna, a fluid compartment at the base of the brain. Simultaneously, they induce systemic hypertonicity, which drives cerebrospinal fluid and the viral vectors into the glymphatic network. This allows broad distribution throughout the brain parenchyma while reducing off-target transduction of peripheral organs .

Two Key Innovations Combined

1. In vivo capsid selection in human glial chimeric mice — A library of capsid-modified AAV5 vectors was screened in mice engrafted with human glial progenitor cells (hGPCs). Using PCR-based tracking against visceral organs, the team identified variants that preferentially infect human GPCs, astrocytes, and oligodendrocytes in a biologically relevant brain environment .

2. Glymphatic delivery via cisterna magna injection paired with hypertonic treatment — Intracisternal delivery combined with systemic hypertonicity exploits the glymphatic system's fluid flow to spread vectors brain-wide while avoiding the BBB and minimizing off-target systemic transduction .

This dual approach solves two long-standing obstacles simultaneously: penetrating the BBB and selectively targeting glial cells rather than neurons.

Therapeutic Applications Targeted

The platform is positioned for disorders involving glial dysfunction and white matter loss :

• Multiple sclerosis
• Huntington's disease
• Age-related white matter loss
• Rare childhood neurological conditions (childhood white matter disorders)

These conditions share a common feature: damage to glial cells and the white matter tracts they support. By delivering therapeutic genes directly to glial progenitor cells, the platform aims to repair or replace dysfunctional cells at their source.

Remaining Hurdles Before Human Translation

While the approach represents a significant preclinical advance, several hurdles must be overcome before it reaches patients. The URMC news release and published preprint do not specify a detailed list of remaining roadblocks, but the following gaps and general AAV gene therapy challenges are evident from the broader literature:

• Safety and immunogenicity — AAV vectors can trigger immune responses. CNS-delivered AAV5 carrying non-self proteins has been shown to elicit full immune reactions in brain tissue , and across 255 clinical trials, serious adverse events including hepatotoxicity and neurotoxicity have been reported .

• Dose-dependent toxicity risk — Systemic AAV doses above approximately 1 × 10¹⁴ viral genomes per kilogram are associated with acute and delayed toxicities such as thrombotic microangiopathy and liver damage . The glymphatic approach aims to reduce required doses, but dose-toxicity thresholds in humans remain unestablished.

• Translation from human-glial chimeric mice to humans — The capsids were evolved in a mouse model harboring human glial cells. Performance, tropism, and safety may differ in an intact human brain.

• Durability and long-term expression — How long transgene expression persists and whether repeat dosing is needed or feasible via the glymphatic route is not yet known.

• Manufacturing and scalability — Producing engineered AAV5 capsids at clinical-grade scale for brain delivery has not been addressed.

• Regulatory and clinical trial pathway — No clinical trial has been announced; the study remains at the preclinical proof-of-concept stage.

Bottom line: The platform is a significant preclinical advance that addresses two long-standing obstacles — BBB penetration and glial cell targeting — simultaneously. However, it has not yet entered human trials, and standard AAV safety, immunogenicity, dosing, and manufacturing questions remain open.